Leonora E. Long

Leonora E. Long

Auto-generated profile, based on publicly available information

Leonora E. Long

Department of Surgery, St George Hospital , Grey St, Kogarah, NSW 2217 , Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2007 in Neuropsychopharmacology
Verified
Journal Article
Closed access
HQHeidi R Quinn
Heidi R Quinn
IMIzuru Matsumoto
Izuru Matsumoto
PCPaul D Callaghan
Paul D Callaghan
LLLeonora E Long
Leonora E Long
JAJonathon C Arnold
Jonathon C Arnold
IMIain S McGregor
Iain S McGregor

29 September 2009 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
LLLeonora E. Long
Leonora E. Long
RCRose Chesworth
Rose Chesworth
XHXu-Feng Huang
Xu-Feng Huang
IMIain S. McGregor
Iain S. McGregor
JAJonathon C. Arnold
Jonathon C. Arnold
TKTim Karl
Tim Karl
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the

11 June 2011 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
CKCharlotte Klein
Charlotte Klein
EKEmily Karanges
Emily Karanges
ASAdena Spiro
Adena Spiro
AWAlexander Wong
Alexander Wong
JSJarrah Spencer
Jarrah Spencer
IMIain S. McGregor
Iain S. McGregor

1 January 2013 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
VCVibeke S. Catts
Vibeke S. Catts
SFSamantha J. Fung
Samantha J. Fung
LLLeonora E. Long
Leonora E. Long
DJDipesh Joshi
Dipesh Joshi
AVAns Vercammen
Ans Vercammen
CWCynthia Shannon Weickert
Cynthia Shannon Weickert
The schizophrenia brain is differentiated from the normal brain by subtle changes, with significant overlap in measures between normal and disease states. For the past 25 years, schizophrenia has increasingly been considered a neurodevelopmental disorder. This frame of reference challenges biological researchers to consider how pathological changes identified in adult brain tissue can be accounted for by aberrant developmental processes occurring during fetal, childhood, or adolescent periods. To place schizophrenia neuropathology in a neurodevelopmental context requires solid, scrutinized evidence of changes occurring during normal development of the human brain, particularly in the cortex; however, too often data on normative developmental change are selectively referenced. This paper focuses on the development of the prefrontal cortex and charts major molecular, cellular, and behavioral events on a similar time line. We first consider the time at which human cognitive abilities such as selective attention, working memory, and inhibitory control mature, emphasizing that attainment of full adult potential is a process requiring decades. We review the timing of neurogenesis, neuronal migration, white matter changes (myelination), and synapse development. We consider how molecular changes in neurotransmitter signaling pathways are altered throughout life and how they may be concomitant with cellular and cognitive changes. We end with a consideration of how the response to drugs of abuse changes with age. We conclude that the concepts around the timing of cortical neuronal migration, interneuron maturation, and synaptic regression in humans may need revision and include greater emphasis on the protracted and dynamic changes occurring in adolescence. Updating our current understanding of post-natal neurodevelopment should aid researchers in interpreting gray matter changes and derailed neurodevelopmental processes that could underlie emergence of psychosis.

27 July 2005 in Neuropsychopharmacology
Verified
Journal Article
Closed access
LLLeonora E Long
Leonora E Long
DMDaniel T Malone
Daniel T Malone
DTDavid A Taylor
David A Taylor

24 July 2012 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
LLLeonora E Long
Leonora E Long
JLJonna Lind
Jonna Lind
MWMaree Webster
Maree Webster
CWCynthia Shannon Weickert
Cynthia Shannon Weickert
Background: Endocannabinoids provide control over cortical neurotransmission. We investigated the developmental expression of key genes in the endocannabinoid system across human postnatal life and determined whether they correspond to the development of markers for inhibitory interneurons, which shape cortical development. We used microarray with qPCR validation and in situ hybridisation to quantify mRNA for the central endocannabinoid receptor CB1R, endocannabinoid synthetic enzymes (DAGLα for 2-arachidonylglycerol [2-AG] and NAPE-PLD for anandamide), and inactivating enzymes (MGL and ABHD6 for 2-AG and FAAH for anandamide) in human dorsolateral prefrontal cortex (39 days - 49 years). Results: CB1R mRNA decreases until adulthood, particularly in layer II, after peaking between neonates and toddlers. DAGLα mRNA expression is lowest in early life and adulthood, peaking between school age and young adulthood. MGL expression declines after peaking in infancy, while ABHD6 increases from neonatal age. NAPE-PLD and FAAH expression increase steadily after infancy, peaking in adulthood. Conclusions: Stronger endocannabinoid regulation of presynaptic neurotransmission in both supragranular and infragranular cortical layers as indexed through higher CB1R mRNA may occur within the first few years of human life. After adolescence, higher mRNA levels of the anandamide synthetic and inactivating enzymes NAPE-PLD and FAAH suggest that a late developmental switch may occur where anandamide is more strongly regulated after adolescence than earlier in life. Thus, expression of key genes in the endocannabinoid system changes with maturation of cortical function.